A Phase 2 interventional study of BIMERVAX and SIIV in SARS CoV 2 Infection and Influenza, Human, sponsored by Hipra Scientific, S.L.U. Completed at 8 sites in Spain. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Hipra Scientific, S.L.U · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 401 studies in COVID-19 with a site in Spain — 25 open to participants now, 32 under way, 7 of them phase 3. COVID-19 · Spain.
Among the 401 studies in COVID-19 with a site in Spain, this one is the 85th largest by enrollment of the 254 interventional ones that give a count, is one of 22 that started in 2023, is one of 54 in phase 2, and was the 370th registered.
7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.
Browse COVID-19 studies →25 of the 401 studies in COVID-19 with a site in Spain are open now. Recruiting first, the newest first:
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · Sites in Spain
Ages 18+
Pfizer · Sites in Spain, United States, Argentina and 15 more countries
Ages 18+
Pfizer · Sites in Spain, United States, Argentina and 16 more countries
Ages 12+
Merck Sharp & Dohme LLC · Sites in Spain, United States, Argentina and 21 more countries
Ages 18+
PEACHES BIOTECH · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
401 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 84 · Phase 3 90 · Phase 4 14
First in 2015; this study’s year is marked. 22 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 279 is above the median of 102 across 4,369 interventional studies indexed under COVID-19.
Median enrollment 132 across the 254 interventional studies, 600 across the 146 observational. Of the 287 that completed or were terminated, 73 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 401 have an industry lead sponsor. The 10 most frequent:
Hipra Scientific, S.L.U is the lead sponsor of 8 studies on the registry; none are open to participants now.
Hipra Scientific, S.L.U has 8 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
8 of the studies in COVID-19 with a site in Spain that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT06544395Clinica Gema LeonEfficacy of Non-invasive Neuromodulation Treatments for COVID-19 Sequelae | 2026-12-01 |
| NCT07197164Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la CienciaSafety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients | 2026-12-30 |
Add all 8 to your calendar (.ics) → With an account.
Among the 401 studies in COVID-19 with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen inactivated adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19.
This is a Phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen inactivated adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19.
In this study approximately 300 adults aged 65 or older will be enrolled and followed for 1 month after study treatment. Safety and immunogenicity of all participants will be assessed.
The participants will be randomised 1:1:1 to one of the following three cohorts:
All participants will receive two administrations at Day 0 and will be followed for 1 month. All subjects will be closely observed for 15 minutes after vaccination on site. The study will be double-blind, both the participant and the physician (care provider) will be blinded. Participants will be provided with a participant paper diary on Day 0 to record solicited local and systemic reactions after vaccination through Day 7. Unsolicited local and systemic adverse events, SAEs and AESIs, will be recorded through Day 28 (end of study).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: BIMERVAX · Biological: SIIV
Biological: BIMERVAX
Biological: SIIV
One dose of booster vaccine
One dose
Number, percentage, and characteristics of solicited local and systemic reactions through Day 7 after vaccination.
To assess and compare the safety and tolerability of BIMERVAX® coadministered with SIIV in adults with respect to each vaccine administered alone.
Time frame: Day 0, Day 7
Number, percentage, and characteristics of unsolicited local and systemic adverse events (AEs) through the end of the study.
To assess and compare the safety and tolerability of BIMERVAX® coadministered with SIIV in adults with respect to each vaccine administered alone.
Time frame: Day 0, Day 7, Day 28
Number and percentage of serious adverse events (SAEs) through the end of the study.
To assess and compare the safety and tolerability of BIMERVAX® coadministered with SIIV in adults with respect to each vaccine administered alone.
Time frame: Day 0, Day 7, Day 28
Number and percentage of adverse events of special interest (AESI) through the end of the study
To assess and compare the safety and tolerability of BIMERVAX® coadministered with SIIV in adults with respect to each vaccine administered alone.
Time frame: Day 0, Day 7, Day 28
Total binding antibody titers against SARS-CoV-2 RBD at Days 0 and 28
To determine and compare the immunogenicity measured by means of total antibodies against the Receptor Binding Domain of the Spike protein of SARS-CoV-2, measured by an electrochemiluminescence immunoassay (ECLIA) at Baseline and Day 28, in participants vaccinated with BIMERVAX® alone or coadministered with SIIV.
Time frame: Day 0, Day28
Geometric mean fold rise in total binding antibody titers against SARS-CoV-2 RBD at Day 28
To determine and compare the geometric mean fold rise (GMFR) in total binding antibody titers against the Receptor Binding Domain of the Spike protein of SARS-CoV-2 from Baseline to Day 28, in participants vaccinated with BIMERVAX® alone or coadministered with SIIV.
Time frame: Day 0, Day28
Influenza strain-specific HAI antibody titers at Days 0 and 28
To determine and compare the immunogenicity measured by influenza strain-specific antibody titers using a haemagglutination inhibition (HAI) assay at Baseline and Day 28, in participants vaccinated with SIIV alone or coadministered with BIMERVAX®
Time frame: Day 0, Day28
Geometric mean fold rise in influenza strain-specific HAI antibody titers at Day 28
To determine and compare the geometric mean fold rise (GMFR) in influenza strain-specific antibody titers measured by haemagglutination inhibition (HAI) assay from Baseline to Day 28, in participants vaccinated with SIIV alone or coadministered with BIMERVAX®.
Time frame: Day 0, Day28
Ran from Sep 2023 to primary completion in Nov 2023, 1 month.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 1 month is below that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2023 → Nov 2023, on Nov 17, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hipra Scientific, S.L.U